| Date | Title | Description |
| 27.02.2026 | Health Frontiers: Cancer Breakthroughs Meet Policy Crossroads | The landscape of health evolves rapidly. Scientific innovation pushes new boundaries. Policy decisions face intense scrutiny. Recent developments highlight this dynamic tension.
Norway-based Oncoinvent ASA makes significant strides. The bio... |
| 26.02.2026 | Oncoinvent ASA: Second half 2025 results | Oncoinvent ASA: Second half 2025 results
Thu, Feb 26, 2026 07:00 CET Report this content
Oslo, Norway, 26 February 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate can... |
| 29.10.2025 | BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent | BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent
Wed, Oct 29, 2025 07:00 CET Report this content
Reference is made to the joint stock exchange announcement made on 24 October 2025 by BerGenBio ASA and Oncoinvent AS... |
| 29.10.2025 | Merger of BerGenBio and Oncoinvent completed | Merger of BerGenBio and Oncoinvent completed
Wed, Oct 29, 2025 17:35 CET Report this content
Oslo, 29 October 2025 – Reference is made to the previous stock exchange announcements made in connection with the combination of BerGenBio ASA and... |
| 29.10.2025 | BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent | BerGenBio and Oncoinvent – Last day of trading in the shares of Oncoinvent
Wed, Oct 29, 2025 07:00 CET Report this content
Bergen, 29 October 2025; Reference is made to the joint stock exchange announcement made on 24 October 2025 by BerGen... |
| 28.10.2025 | BerGenBio ASA: Approval and publication of prospectus | BerGenBio ASA: Approval and publication of prospectus
Tue, Oct 28, 2025 10:42 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRA... |
| 24.10.2025 | BerGenBio and Oncoinvent – Key Dates for Completion of Merger | BerGenBio and Oncoinvent – Key Dates for Completion of Merger
Fri, Oct 24, 2025 07:59 CET Report this content
Bergen, Norway and Oslo, Norway, 24 October 2025 – Reference is made to the joint stock exchange announcement on 30 June 2025 by B... |
| 24.10.2025 | BerGenBio and Oncoinvent – Key Dates for Completion of Merger | BerGenBio and Oncoinvent – Key Dates for Completion of Merger
Fri, Oct 24, 2025 08:00 CET Report this content
Bergen, Norway and Oslo, Norway, 24 October 2025 – Reference is made to the joint stock exchange announcement on 30 June 2025 by B... |
| 17.09.2025 | BerGenBio ASA: Updated information regarding the contemplated Rights Issue and Merger | BerGenBio ASA: Updated information regarding the contemplated Rights Issue and Merger
Wed, Sep 17, 2025 08:55 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, ... |
| 17.09.2025 | BerGenBio ASA: Updated Key Information related to the contemplated Rights Issue | BerGenBio ASA: Updated Key Information related to the contemplated Rights Issue
Wed, Sep 17, 2025 08:56 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HO... |
| 27.08.2025 | Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer | Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer
Wed, Aug 27, 2025 07:00 CET Report this content
Oncoinvent reports continued progress in the ongoing Phase 2 trial in ov... |
| 20.08.2025 | BerGenBio First half results 2025 | BerGenBio First half results 2025
Wed, Aug 20, 2025 07:00 CET Report this content
Bergen, Norway, 20 August 2025 – BerGenBio ASA (OSE: BGBIO today announced financial results for the first half 2025.
Highlights, including post period:
In Fe... |
| 05.08.2025 | BerGenBio ASA – Updated key information related to the rights issue | BerGenBio ASA – Updated key information related to the rights issue
Tue, Aug 05, 2025 16:49 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPEC... |
| 04.08.2025 | Oncoinvent shareholders approve the merger plan with BerGenBio | Oncoinvent shareholders approve the merger plan with BerGenBio
Mon, Aug 04, 2025 13:53 CET Report this content
Oslo, Norway, 4 August 2024 – Reference is made to the joint stock exchange announcement made on 30 June 2025 by Oncoinvent ASA (... |
| 04.08.2025 | BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue | BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue
Mon, Aug 04, 2025 13:40 CET Report this content
Bergen, 4 August 2025: Reference is made to the joint stock exchange announcement made on 30 June 2025 by Ber... |
| 03.07.2025 | BerGenBio ASA: Notice of Extraordinary General Meeting | BerGenBio ASA: Notice of Extraordinary General Meeting
Thu, Jul 03, 2025 14:53 CET Report this content
Bergen, Norway – 3 July 2025: BerGenBio ASA (OSE:BGBIO) will hold an Extraordinary General Meeting virtually on 4 August 2025 at 12:00 PM... |
| 01.07.2025 | The Dance of Capital: BerGenBio and Hacksaw's Bold Moves in the Market | In the world of finance, the rhythm of capital flows can be both exhilarating and daunting. Recently, two companies, BerGenBio ASA and Hacksaw, have taken significant steps that illustrate this dance. Each move is a calculated step toward g... |
| 30.06.2025 | BerGenBio ASA – Key information related to the rights issue | BerGenBio ASA – Key information related to the rights issue
Mon, Jun 30, 2025 22:29 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMI... |
| 26.06.2025 | BerGenBio ASA – Minutes from the annual general meeting 2025 | BerGenBio ASA – Minutes from the annual general meeting 2025
Thu, Jun 26, 2025 11:29 CET Report this content
Bergen, 26 June 2025: BerGenBio ASA held its annual general meeting today digitally through Lumi AGM. All resolutions were made in ... |
| 04.06.2025 | The Shifting Sands of European Business: A Look at Recent Developments | In the ever-evolving landscape of European business, recent announcements from three companies—BerGenBio ASA, Zinzino AB, and Nynas AB—paint a vivid picture of the challenges and triumphs that define the corporate world today. Each company ... |
| 03.06.2025 | BerGenBio ASA: Update on Strategic Review Process and Status of Activities | BerGenBio ASA: Update on Strategic Review Process and Status of Activities
Tue, Jun 03, 2025 19:21 CET Report this content
Bergen, 3 June 2025 – Reference is made to previous stock exchange announcements from BerGenBio ASA ("BerGenBio&... |
| 03.06.2025 | BerGenBio ASA: Notice of Annual General Meeting | BerGenBio ASA: Notice of Annual General Meeting
Tue, Jun 03, 2025 15:55 CET Report this content
Bergen, Norway – 3 June 2025: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 26 June 2025 at 10:00 hours (CES... |
| 29.04.2025 | BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar | BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar
Tue, Apr 29, 2025 22:03 CET Report this content
Bergen, Norway – 29 April 2025 – BerGenBio ASA (OSE: BGBIO), a clinical... |
| 27.03.2025 | A New Dawn in Medicine: BerGenBio's Breakthrough in Acute Myeloid Leukemia and Inner Brightness's Probiotic Revolution | In the ever-evolving landscape of healthcare, two recent announcements shine like beacons of hope. BerGenBio, a biopharmaceutical company, has unveiled promising results in the fight against relapsed/refractory Acute Myeloid Leukemia (AML).... |
| 26.03.2025 | BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients | BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients
Wed, Mar 26, 2025 07:00 CET Report this content
The article identifies promising survival results in relapsed/r... |
| 18.03.2025 | Navigating the Waters of Corporate Strategy: BerGenBio and Multiconsult ASA Take Bold Steps | In the ever-shifting landscape of corporate finance, companies often find themselves at a crossroads. Two firms, BerGenBio ASA and Multiconsult ASA, recently made headlines with strategic maneuvers that reflect the complexities of modern bu... |
| 17.03.2025 | BerGenBio announces advancement of its strategic review | BerGenBio announces advancement of its strategic review
Mon, Mar 17, 2025 07:00 CET Report this content
Bergen, Norway, March 17, 2025 – Reference is made to the stock exchange announcement on 25 February 2025 from BerGenBio ASA (OSE: BGBIO... |
| 01.03.2025 | BerGenBio Faces Crossroads: Discontinuation of Key Study and Strategic Reassessment | In the world of biopharmaceuticals, the path to success is often fraught with challenges. BerGenBio ASA, a clinical-stage company based in Norway, recently found itself at a significant crossroads. The company announced the discontinuation ... |
| 26.02.2025 | BerGenBio Fourth Quarter Results 2024 | BerGenBio Fourth Quarter Results 2024
Wed, Feb 26, 2025 07:00 CET Report this content
Bergen, Norway, February 26, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibit... |
| 25.02.2025 | BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives | BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives
Tue, Feb 25, 2025 19:58 CET Report this content
Bergen, Norway, February 25, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharm... |
| 18.02.2025 | BerGenBio ASA: Invitation to fourth quarter 2024 results webcast | BerGenBio ASA: Invitation to fourth quarter 2024 results webcast
Tue, Feb 18, 2025 07:00 CET Report this content
Bergen, Norway, 18 February 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, sel... |
| 07.01.2025 | BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial | BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial
Tue, Jan 07, 2025 07:00 CET Report this content
Bergen, Norway, January 7, 2025 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical compan... |
| 26.11.2024 | BerGenBio to Present Company Update at DNB Nordic Healthcare Conference | BerGenBio to Present Company Update at DNB Nordic Healthcare Conference
Tue, Nov 26, 2024 08:00 CET Report this content
BERGEN, Norway, November 26, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing no... |
| 20.11.2024 | BerGenBio Appoints Olav Hellebø as CEO | BerGenBio Appoints Olav Hellebø as CEO
Wed, Nov 20, 2024 20:30 CET Report this content
Bergen, Norway, November 20, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibit... |
| 13.11.2024 | BerGenBio Third Quarter Results 2024 | BerGenBio Third Quarter Results 2024
Wed, Nov 13, 2024 07:00 CET Report this content
Bergen, Norway, November 13, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibito... |
| 06.11.2024 | BerGenBio ASA: Invitation to third quarter 2024 results webcast | BerGenBio ASA: Invitation to third quarter 2024 results webcast
Wed, Nov 06, 2024 07:00 CET Report this content
Bergen, Norway, 5 November 2024 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, select... |
| 11.10.2024 | BerGenBio ASA: Navigating Change in the Biopharmaceutical Landscape | In the world of biopharmaceuticals, change is the only constant. BerGenBio ASA, a clinical-stage company based in Bergen, Norway, is no stranger to this reality. On October 10, 2024, the company held an Extraordinary General Meeting (EGM) a... |
| 11.10.2024 | BerGenBio Faces Transition Amid Promising Drug Developments | In the world of biopharmaceuticals, change is a constant. BerGenBio ASA, a clinical-stage company based in Bergen, Norway, is navigating a pivotal moment. The company is at the forefront of developing selective AXL inhibitors, particularly ... |
| 11.10.2024 | BerGenBio's Promising Path in NSCLC Treatment: A Closer Look at Recent Developments | In the world of oncology, every breakthrough feels like a small victory in a long, arduous battle. BerGenBio ASA, a biopharmaceutical company based in Norway, is making strides in the fight against Non-Small Cell Lung Cancer (NSCLC). Their ... |
| 10.10.2024 | BerGenBio ASA: Minutes from Extraordinary General Meeting | BerGenBio ASA: Minutes from Extraordinary General Meeting
Thu, Oct 10, 2024 11:07 CET Report this content
Bergen, Norway,10 October 2024 – An Extraordinary general meeting of BerGenBio ASA was virtually held today 10 October 2024 at 10.00 C... |
| 10.10.2024 | CEO Martin Olin steps down | CEO Martin Olin steps down
Thu, Oct 10, 2024 21:31 CET Report this content
Bergen, Norway, 10 October 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet ... |
| 07.10.2024 | BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients | BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients
Mon, Oct 07, 2024 07:00 CET Report this content
Ph1b data support safety, predictable PK and adequate plasma exposure
Bergen, Norway, October 7, 2024... |
| 19.09.2024 | BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING | BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
Thu, Sep 19, 2024 15:00 CET Report this content
Bergen, Norway – 19 September 2024: BerGenBio ASA (OSE:BGBIO) will be holding a Extraordinary General Meeting virtually on 10 October 202... |
| 09.09.2024 | BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference | BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference
Mon, Sep 09, 2024 15:24 CET Report this content
Bergen, Norway, September 9, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical com... |
| 21.08.2024 | BerGenBio Second Quarter Results 2024: Solid clinical and financial progress | BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
Wed, Aug 21, 2024 07:00 CET Report this content
Bergen, Norway, August 21, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing... |
| 20.08.2024 | BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer | BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer
Tue, Aug 20, 2024 07:00 CET Report this content
Bergen, Norway, August 20, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage bi... |
| 15.08.2024 | BerGenBio ASA: Navigating Change in the Biopharmaceutical Landscape | In the ever-evolving world of biopharmaceuticals, BerGenBio ASA stands at a crossroads. This clinical-stage company, based in Bergen, Norway, is making waves with its innovative approach to treating aggressive diseases. As it prepares to un... |
| 15.08.2024 | BerGenBio ASA: Registration of share capital reduction | BerGenBio ASA: Registration of share capital reduction
Thu, Aug 15, 2024 09:57 CET Report this content
Bergen, 15 August 2024: Reference is made to the stock exchange announcement made by BerGenBio ASA (the "Company") on 23 May 20... |
| 13.08.2024 | BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast | BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast
Tue, Aug 13, 2024 07:00 CET Report this content
Bergen, Norway, 13 August 2024 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing... |
| 29.07.2024 | BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial | BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial
Mon, Jul 29, 2024 07:00 CET Report this content
BerGenBio receives positive recommendation from independent
Data and Safety Monitoring Board... |
| 26.06.2024 | BerGenBio ASA: Grant of share options | BerGenBio ASA: Grant of share options
Wed, Jun 26, 2024 17:35 CET Report this content
Bergen, Norway, 26 June 2024 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinas... |
| 03.06.2024 | BerGenBio ASA – Registration of reverse share split | BerGenBio ASA – Registration of reverse share split
Mon, Jun 03, 2024 18:02 CET Report this content
Bergen, Norway, 3 June 2024. Reference is made to the stock exchange announcement made by BerGenBio ASA (the "Company") on 23 May ... |
| 30.05.2024 | BerGenBio ASA - Ex. reverse share split and change of ISIN today | BerGenBio ASA - Ex. reverse share split and change of ISIN today
Thu, May 30, 2024 07:00 CET Report this content
Issuer name: BerGenBio ASA
Ex. date: 30 May 2024
Type of corporate action: Reverse share split
Reverse split ratio: One hundred... |
| 29.05.2024 | BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development | BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development
Wed, May 29, 2024 07:00 CET Report this content
Bergen, Norway, May 29, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developi... |
| 28.05.2024 | BerGenBio ASA - Key information relating to the reverse share split and change of ISIN | BerGenBio ASA - Key information relating to the reverse share split and change of ISIN
Tue, May 28, 2024 14:00 CET Report this content
Bergen, Norway, 28 May 2024: Reference is made to the stock exchange announcement published by BerGenBio ... |
| 28.05.2024 | BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi® | BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®
Tue, May 28, 2024 15:11 CET Report this content
Bergen, Norway, May 28, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company devel... |
| 28.05.2024 | BerGenBio ASA: New share capital registered | BerGenBio ASA: New share capital registered
Tue, May 28, 2024 10:07 CET Report this content
Bergen, Norway, 28 May 2024: Reference is made to the stock exchange announcement by BerGenBio ASA (the "Company") on 23 May 2024 regardin... |
| 23.05.2024 | BerGenBio ASA – Minutes from the annual general meeting 2024 | BerGenBio ASA – Minutes from the annual general meeting 2024
Thu, May 23, 2024 17:15 CET Report this content
Bergen, 23 May 2024: BerGenBio ASA held its annual general meeting today digitally through Lumi AGM. All resolutions were made in a... |
| 22.05.2024 | BerGenBio ASA: Invitation to first quarter 2024 results webcast | BerGenBio ASA: Invitation to first quarter 2024 results webcast
Wed, May 22, 2024 07:00 CET Report this content
Bergen, Norway, 22 May 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective... |
| 30.04.2024 | BerGenBio ASA: Notice of Annual General Meeting | BerGenBio ASA: Notice of Annual General Meeting
Tue, Apr 30, 2024 14:00 CET Report this content
Bergen, Norway – 30 April 2024: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 23 May 2024 at 16:00 hours (CE... |
| 30.04.2024 | BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2023 | BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2023
Tue, Apr 30, 2024 13:00 CET Report this content
Bergen, Norway – 30 April 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company ... |
| 25.04.2024 | BerGenBio ASA: New share capital registered | BerGenBio ASA: New share capital registered
Thu, Apr 25, 2024 12:55 CET Report this content
Bergen, Norway, 25 April 2024 - Reference is made to the stock exchange announcement by BerGenBio ASA (the "Company") on 16 April 2024 reg... |
| 17.04.2024 | BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission | BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission
Wed, Apr 17, 2024 17:10 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRA... |
| 16.04.2024 | BerGenBio ASA: Final results for the last exercise period for warrants issued in connection with rights issue | BerGenBio ASA: Final results for the last exercise period for warrants issued in connection with rights issue
Tue, Apr 16, 2024 14:15 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, J... |
| 15.04.2024 | BerGenBio ASA: Mandatory notification of trade by primary insiders and close associates | BerGenBio ASA: Mandatory notification of trade by primary insiders and close associates
Mon, Apr 15, 2024 10:58 CET Report this content
Bergen, Norway, 15 April 2024 - Reference is made to the stock exchange announcement published by BerGen... |
| 15.04.2024 | BerGenBio ASA: Last day of the last exercise period for warrants issued in connection with rights issue | BerGenBio ASA: Last day of the last exercise period for warrants issued in connection with rights issue
Mon, Apr 15, 2024 07:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, ... |
| 08.04.2024 | BerGenBio ASA: Last day of trading in warrants | BerGenBio ASA: Last day of trading in warrants
Mon, Apr 08, 2024 07:15 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION... |
| 03.04.2024 | BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue | BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue
Wed, Apr 03, 2024 13:22 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, J... |
| 02.04.2024 | BerGenBio ASA: Commencement of the last exercise period for warrants issued in connection with rights issue | BerGenBio ASA: Commencement of the last exercise period for warrants issued in connection with rights issue
Tue, Apr 02, 2024 08:50 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAP... |
| 02.04.2024 | BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025 | BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025
Tue, Apr 02, 2024 07:55 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE... |
| 27.03.2024 | BerGenBio ASA: Exercise price in the last exercise period for warrants issued in connection with rights issue | BerGenBio ASA: Exercise price in the last exercise period for warrants issued in connection with rights issue
Wed, Mar 27, 2024 15:59 CET Report this content
Bergen, Norway, 27 March 2024 – Reference is made to the stock exchange announceme... |
| 20.03.2024 | BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation | BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation
Wed, Mar 20, 2024 17:15 CET Report this content
BerGenBio receives positive recommendation from independent
Data and Safety Monito... |
| 04.03.2024 | BerGenBio to Participate in Carnegie Nordic Healthcare Seminar | BerGenBio to Participate in Carnegie Nordic Healthcare Seminar
Mon, Mar 04, 2024 07:00 CET Report this content
BERGEN, Norway, March 4, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selectiv... |
| 19.02.2024 | BerGenBio ASA – Approval and publication of a prospectus supplement | BerGenBio ASA – Approval and publication of a prospectus supplement
Mon, Feb 19, 2024 17:58 CET Report this content
Bergen 19 February 2024 - Reference is made to the stock exchange announcement on 7 December 2023 regarding the approval and... |
| 14.02.2024 | BerGenBio’s Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum | BerGenBio’s Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum
Wed, Feb 14, 2024 07:00 CET Report this content
Bergen (Norway), February 14, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developi... |
| 07.02.2024 | BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections | BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections
Wed, Feb 07, 2024 12:00 CET Report this content
Bergen, Norway, February 7, 2024, – BerGenBio ASA (OSE: BGBIO), a... |
| 06.02.2024 | BerGenBio ASA: Invitation to fourth quarter 2023 results webcast | BerGenBio ASA: Invitation to fourth quarter 2023 results webcast
Tue, Feb 06, 2024 07:00 CET Report this content
Bergen, Norway, 6 February 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, sele... |
| 15.12.2023 | BerGenBio announces closure of EU-SolidAct bemcentinib study arm in hospitalized COVID-19 patients | BerGenBio announces closure of EU-SolidAct bemcentinib study arm in hospitalized COVID-19 patients
Fri, Dec 15, 2023 16:48 CET Report this content
BERGEN, Norway, December 15, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceu... |
| 12.12.2023 | BerGenBio to Present at DNB Nordic Healthcare Conference | BerGenBio to Present at DNB Nordic Healthcare Conference
Tue, Dec 12, 2023 07:00 CET Report this content
Bergen, Norway, December 12, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective ... |
| 11.12.2023 | BerGenBio Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting | BerGenBio Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting
Mon, Dec 11, 2023 07:00 CET Report this content Bemcentinib is an oral highly selective AXL inhibitor in development for cancer and severe r... |
| 08.12.2023 | BerGenBio ASA: Grant of share options | BerGenBio ASA: Grant of share options
Fri, Dec 08, 2023 18:10 CET Report this content
Bergen, Norway, 8 December 2023 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL ki... |
| 08.12.2023 | BerGenBio ASA - New share capital registered | BerGenBio ASA - New share capital registered
Fri, Dec 08, 2023 08:32 CET Report this content
Bergen 8 December 2023 - Reference is made to the stock exchange announcement by BerGenBio ASA (the "Company") on 30 November 2023 regard... |
| 07.12.2023 | BerGenBio ASA: Approval and publication of prospectus | BerGenBio ASA: Approval and publication of prospectus
Thu, Dec 07, 2023 14:05 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA, JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURIS... |
| 07.12.2023 | BerGenBio ASA – Updated timeline for delivery of new shares | BerGenBio ASA – Updated timeline for delivery of new shares
Thu, Dec 07, 2023 10:47 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMI... |
| 30.11.2023 | BerGenBio ASA – Final results for the first exercise period for warrants issued in connection with rights issue | BerGenBio ASA – Final results for the first exercise period for warrants issued in connection with rights issue
Thu, Nov 30, 2023 17:30 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED S... |
| 29.11.2023 | BerGenBio ASA – Preliminary results for the first exercise period for warrants issued in connection with rights issue | BerGenBio ASA – Preliminary results for the first exercise period for warrants issued in connection with rights issue
Wed, Nov 29, 2023 19:00 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UN... |
| 28.11.2023 | BerGenBio ASA – Last day of the first exercise period for warrants issued in connection with rights issue | BerGenBio ASA – Last day of the first exercise period for warrants issued in connection with rights issue
Tue, Nov 28, 2023 07:00 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,... |
| 24.11.2023 | BerGenBio ASA – Information about the first exercise period for warrants issued in connection with rights issue | BerGenBio ASA – Information about the first exercise period for warrants issued in connection with rights issue
Fri, Nov 24, 2023 13:46 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED S... |
| 15.11.2023 | BerGenBio ASA - Commencement of the first exercise period for warrants issued in connection with rights issue | BerGenBio ASA - Commencement of the first exercise period for warrants issued in connection with rights issue
Wed, Nov 15, 2023 07:00 CET Report this content
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STA... |
| 14.11.2023 | BerGenBio Reports Third Quarter 2023 Financial Results | BerGenBio Reports Third Quarter 2023 Financial Results
Tue, Nov 14, 2023 07:00 CET Report this content
BERGEN, Norway, November 14, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective A... |
| 06.11.2023 | BerGenBio ASA: Invitation to third quarter 2023 results webcast | BerGenBio ASA: Invitation to third quarter 2023 results webcast
Mon, Nov 06, 2023 12:00 CET Report this content
Bergen, Norway, 6 November 2023 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, select... |
| 06.11.2023 | BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC | BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC
Mon, Nov 06, 2023 07:00 CET Report this content
Presented at 2023 SITC Meeting
- A pre-planned biomarker analysis of patients treated with bemcentinib in combination with KEYTRUDA... |
| 02.11.2023 | BerGenBio Announces Poster Presentation at Upcoming ASH Meeting | BerGenBio Announces Poster Presentation at Upcoming ASH Meeting
Thu, Nov 02, 2023 14:00 CET Report this content
BERGEN, Norway, November 2, 2023, BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selec... |
| 31.10.2023 | BerGenBio Announces Poster Presentation at Upcoming SITC Meeting | BerGenBio Announces Poster Presentation at Upcoming SITC Meeting
Tue, Oct 31, 2023 14:00 CET Report this content
BERGEN, Norway, October 31, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, sel... |
| 23.10.2023 | New Data on BerGenBio’s Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting | New Data on BerGenBio’s Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting
Mon, Oct 23, 2023 07:30 CET Report this content
BERGEN, Norway, October 23, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutica... |
| 16.10.2023 | Additional data on BerGenBio’s selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting | Additional data on BerGenBio’s selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting
Mon, Oct 16, 2023 07:00 CET Report this content
BERGEN, Norway, October 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biop... |
| 11.09.2023 | BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference | BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference
Mon, Sep 11, 2023 07:00 CET Report this content
- Presentation available September 11, 2023 on BGBIO website -
BERGEN, Norway, September 11, 2023 – Be... |
| 23.08.2023 | BerGenBio Reports Second Quarter 2023 Financial Results | BerGenBio Reports Second Quarter 2023 Financial Results
Wed, Aug 23, 2023 07:00 CET Report this content
BERGEN, Norway, August 23, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL... |
| 22.08.2023 | BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer | BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer
Tue, Aug 22, 2023 10:30 CET Report this content
BERGEN, Norway, August 22, 2023 – BerGenBio A... |
| 16.08.2023 | BerGenBio ASA: Invitation to second quarter and half year 2023 results webcast | BerGenBio ASA: Invitation to second quarter and half year 2023 results webcast
Wed, Aug 16, 2023 07:00 CET Report this content
Bergen, Norway, 16 August 2023 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing... |
